{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:19:33Z","timestamp":1790223573338,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune\u2010related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD\u20101i and 50% of CTLA4i\u2010treated patients. Severe cutaneous irAE do not often occur but could be life\u2010threatening and may persist despite treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real\u2010world, phase IV, post\u2010marketing study using a follow\u2010up questionnaire.<\/jats:p>\n                    <jats:p>Data since November 2016 until March 2021 were obtained from the Melskintox database, a European multicentric biobank dedicated to the follow\u2010up of melanoma and cutaneous adverse events, supported by EADO. The dermatoses reported were pooled into four categories: inflammatory dermatosis, bullous diseases, drug\u2010related eruptions and pigmentary diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Inflammatory benign dermatoses (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200963) represented the most common group of reactions (52.5%), followed by drug\u2010related eruptions (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924, 20%), pigmentary diseases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923, 19.2%) and bullous diseases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910, 8.3%). Grade II (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941, 34.2%) are represented by bullous pemphigoid, eczema, hypodermitis, lichenoid eruption, maculopapular rash, pruritus, psoriasis\u2010like rash, urticarial eruption and vitiligo. Grade III (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918, 15.0%) are represented by bullous pemphigoid, lichenoid eruption and rashes. Grade IV (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092, 1.7%) is only represented by bullous disease. Most cutaneous IrAEs led to immunotherapy continuation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200995, 88.0%). CR is associated with more severe the cutaneous irAEs. We report an average time\u2010to\u2010onset of 208\u2009days and some late\u2010onset events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I\u2013II cutaneous IrAE are easily managed allowing ongoing anticancer treatment. Severe late\u2010onset cutaneous irAE are not uncommon. A dermatological follow\u2010up helps mitigate the risk of life\u2010threatening adverse events. These findings highlight the importance of oncodermatological involvement in management of patients with melanoma receiving immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19112","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:25:01Z","timestamp":1681295101000},"page":"1606-1615","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients\u2014The European MelSkinTox study"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-7888","authenticated-orcid":false,"given":"J.\u2010M.","family":"L'Orphelin","sequence":"first","affiliation":[{"name":"Department of Dermatology Caen\u2010Normandie University Hospital  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cassecuel","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Nantes \u2013 Angers INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kandolf","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Faculty Military Medical Academy  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Harwood","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Floor, South Tower, Royal London Hospital, Barts Health NHS Trust Whitechapel E1 1 BB and Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tookey","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Floor, South Tower, Royal London Hospital, Barts Health NHS Trust Whitechapel E1 1 BB and Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9991","authenticated-orcid":false,"given":"M. H.","family":"Junejo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Floor, South Tower, Royal London Hospital, Barts Health NHS Trust Whitechapel E1 1 BB and Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Floor, South Tower, Royal London Hospital, Barts Health NHS Trust Whitechapel E1 1 BB and Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Department of Dermatology APHP H\u00f4pital Saint Louis  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-8196","authenticated-orcid":false,"given":"Z.","family":"Appalla","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.\u2010M.","family":"Kr\u00e4nke","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-2951","authenticated-orcid":false,"given":"G.","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Modena and Reggio Emilia via del Pozzo 71  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cerasuolo","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Research Unit Caen\u2010Normandy University Hospital  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dujovic","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Faculty Military Medical Academy  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Del\u00a0Marmol","sequence":"additional","affiliation":[{"name":"Department of Dermatology \u2013 H\u00f4pital Erasme Universit\u00e9 Libre de Bruxelles  Bruxelles Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Forschner","sequence":"additional","affiliation":[{"name":"Department of Dermatology Eberhard Karls University  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-780X","authenticated-orcid":false,"given":"C.","family":"Garbe","sequence":"additional","affiliation":[{"name":"Department of Dermatology Eberhard Karls University  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bataille","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hemel Hempstead Hospital NHS  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0878","authenticated-orcid":false,"given":"J. M.","family":"Ressler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sollena","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Dermatology Fondazione Policlinico Universitario A. Gemelli \u2013 IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dompmartin","sequence":"additional","affiliation":[{"name":"Department of Dermatology Caen\u2010Normandie University Hospital  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-6600","authenticated-orcid":false,"given":"K.","family":"Peris","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Dermatology Fondazione Policlinico Universitario A. Gemelli \u2013 IRCCS  Rome Italy"},{"name":"Department of Dermatology Catholic University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-5825","authenticated-orcid":false,"given":"B.","family":"Dreno","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Nantes \u2013 Angers INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"And European Association of Dermato\u2010Oncology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160485"},{"key":"e_1_2_11_3_1","unstructured":"Sant\u00e9 publique France [Internet]. Available from:https:\/\/www.cancer\u2010environnement.fr\/340\u2010Melanome\u2010cutane.ce.aspx#Epid\u00e9miologie"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0578-4"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2625"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19750"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091"},{"issue":"3","key":"e_1_2_11_17_1","first-page":"149","article-title":"Toxic epidermal necrolysis\u2010like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar N","year":"2016","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17855"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16311"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866703"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194928"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T21:28:44Z","timestamp":1692221324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/jdv.19112"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19112","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"2022-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}